Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)
Industry: PharmaceuticalsMajor

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Current Quote*
Last: $13.865
Change: 0.145
Book: $2.591
Volume: 26,618

As Of: 07/16 12:21 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol KNSA

Graphs for KNSA


3 Month Graph


6 Month Graph


1 Year Graph